A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies


The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

Full Title of Study: “A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 29, 2006

Detailed Description

Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.


  • Drug: Deoxycoformycin (DCF)
    • Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.

Arms, Groups and Cohorts

  • Experimental: Deoxycoformycin (DCF)/Pentostatin

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants with Overall Response
    • Time Frame: Baseline and approximately every 3 weeks thereafter
    • Overall responses (OR) of participants with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin defined as Complete Response (CR) and Partial Response (PR).

Participating in This Clinical Trial

Inclusion Criteria

  • Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy. – No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. – Life expectancy of at least 12 weeks. – Performance status equal to or less than Zubrod 2. – Signed informed consent. – Patients with measurable disease. – Age at least 16 years. – Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. – Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal. – Adequate renal function defined as serum creatine less than or equal to 1.5 mg %. Exclusion Criteria:

  • No serious intercurrent illness. – Adequate contraception (if applicable). – NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV. – NO experimental clinical trial within 3 weeks of study entry. – NO patients with active CNS disease. – Full recovery from any prior surgical treatment. – NO active active infections.

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • M.D. Anderson Cancer Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Razelle Kurzrock, MD, Principal Investigator, MD Anderson

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.